
Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.
Jason S. Starr, DO, is an assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at Mayo Clinic.

Published: September 17th 2025 | Updated: